Last updated 3 days ago
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
960 patients around the world
Available in United States, Argentina
EyeBiotech Ltd.
6Research sites
960Patients around the world
This study is for people with
Macular Degeneration
Age-related Macular Degeneration
Requirements for the patient
From 50 Years
All Gender
Medical requirements
- The main inclusion criteria include but are not limited to the following.Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye).The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment.
- The main exclusion criteria include but are not limited to the following.Has uncontrolled blood pressure at screening.History of any prior macular laser photocoagulation in the study eye.History of uveitis in either eye.History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study.Has uncontrolled glaucoma in the study eye.Active retinal disease other than the condition under investigation in the study eye.Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye.
Sites
Fundación Zambrano
Recruiting
Instituto Oftalmológico de Buenos Aires / Oftalmos
Recruiting
Centro Oftalmológico Dr. Daniel Charles
Recruiting
Microcirugía Ocular S.A.
Recruiting
Clínica Privada Ojos Romagosa
Recruiting
Centro Médico Oftalmología Global
Recruiting
StudyMALBEC
SponsorEyeBiotech Ltd.
Study typeInterventional
Conditions
Age-related Macular Degeneration
Requirements
From 50 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07440225
